Mesenchymal stromal cells in hepatic fibrosis/cirrhosis: from pathogenesis to treatment.
Yang X, Li Q, Liu W, Zong C, Wei L, Shi Y, Han Z.
Cell Mol Immunol. 2023 Jun;20(6):583-599. doi: 10.1038/s41423-023-00983-5. Epub 2023 Feb 24.
TGF-beta/SMAD Pathway and Its Regulation in Hepatic Fibrosis.
Xu F, Liu C, Zhou D, Zhang L.
J Histochem Cytochem. 2016 Mar;64(3):157-67. doi: 10.1369/0022155415627681. Epub 2016 Jan 8.
Pathophysiology and Treatment Options for Hepatic Fibrosis: Can It Be Completely Cured?
Khanam A, Saleeb PG, Kottilil S.
Cells. 2021 May 4;10(5):1097. doi: 10.3390/cells10051097.
Hepatic Fibrosis in Dogs.
Eulenberg VM, Lidbury JA.
J Vet Intern Med. 2018 Jan;32(1):26-41. doi: 10.1111/jvim.14891. Epub 2017 Nov 30.
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD.
Palomer X, Wang JR, Escalona C, Wu S, Wahli W, Vázquez-Carrera M.
Trends Pharmacol Sci. 2025 Jun;46(6):551-566. doi: 10.1016/j.tips.2025.03.008. Epub 2025 Apr 28.
Key Players of Hepatic Fibrosis.
Dawood RM, El-Meguid MA, Salum GM, El Awady MK.
J Interferon Cytokine Res. 2020 Oct;40(10):472-489. doi: 10.1089/jir.2020.0059. Epub 2020 Aug 25.
Markers of hepatic fibrosis.
Caballería L, Torán P, Caballería J.
Med Clin (Barc). 2018 Apr 23;150(8):310-316. doi: 10.1016/j.medcli.2017.08.009. Epub 2017 Oct 18.
Hepatic Fibrosis: Emerging Therapies.
Friedman SL.
Dig Dis. 2015;33(4):504-7. doi: 10.1159/000374098. Epub 2015 Jul 6.
Targeting Hepatic Stellate Cell Death to Reverse Hepatic Fibrosis.
Zhang X, Zeng Y, Zhao L, Xu Q, Miao D, Yu F.
Curr Drug Targets. 2023;24(7):568-583. doi: 10.2174/1389450124666230330135834.
CRISPR/dCas9 for hepatic fibrosis therapy: implications and challenges.
Luo N, Zhong W, Li J, Lu J, Dong R.
Mol Biol Rep. 2022 Dec;49(12):11403-11408. doi: 10.1007/s11033-022-07713-6. Epub 2022 Aug 12.
